Searched for
NOVO NORDISK LAWSUIT
Did Ozempic manufacturer Novo Nordisk hide drug death reports? Here’s what FDA said about side-effect reportingDespite ongoing debate, medications such as Ozempic continue to rank among the most commonly prescribed treatments for weight management an...- S&P 500 nears all-time high, Dow Jones, Nasdaq make solid gains, gold price, silver rate, Bitcoin price jump bigNvidia share price was up 2.4 per cent and Broadcom stocks jumped 3.3 per cent. They were two of the strongest forces pushing the S&P 500 u...
- Novo Nordisk sued in US for allegedly monopolizing diabetes drug VictozaDanish drugmaker Novo Nordisk faces a class action lawsuit in New York. The company is accused of using its patents to keep a monopoly on i...
- HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglut...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- Pfizer, Novo Nordisk escalate bidding war for obesity drug developer MetseraA fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...
- Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...
- US court rejects Novo Nordisk's challenge to Medicare drug pricing planA federal appeals court has rejected Novo Nordisk's challenge to Medicare's program allowing drug price negotiations. This ruling is the la...
- Natco Pharma sues Novo Nordisk in generic drug pushThe lawyers representing Natco Pharma informed the court that over the past few months it had approached Novo Nordisk to communicate on its...
- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- Novo Nordisk CEO warns of layoffs as Wegovy challenge heats upNovo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sa...
- Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss dr...
- Funding freeze halted, White House preps for legal battleThe White House plans to contest a court ruling that blocked part of the Trump administration's directive to pause federal financial aid. A...
- Robert F. Kennedy Jr: Trump's biggest anti-establishment bombshell?President-elect Donald Trump has selected Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Se...
- Americans hungry for weight-loss drugs grapple with supply and insurance hurdlesDespite supply chain issues easing, patients seeking weight-loss drugs like Wegovy and Zepbound are turning to cheaper compounded versions ...
- How Indian-American businessman duped Goldman Sachs of Rs 8,300 croreRishi Shah, co-founder of Outcome Health, has been sentenced to seven and a half years in prison for his role in a $1 billion fraud scheme ...
- Novo Nordisk, maker of Ozempic and Wegovy sues two pharmacies for ‘selling impure drugs’Over alleged selling of contaminated drugs, two Florida-based pharmacies have been sued by Novo Nordisk. The company claims that the substa...
- US names first 10 drugs for Medicare price negotiationThe Biden administration has released a list of 10 prescription medicines that will be subject to price negotiations by the U.S. Medicare h...
Load More
